| oxaliplatin / Generic mfg. |
SVOSA, NCT02338518: Comparison of SEEOX and SOX Regimens in Stage ⅢB/ⅢC Gastric Cancer Patients |
|
|
| Active, not recruiting | 3 | 297 | RoW | oxaliplatin, etoposide, pharmorubicin, epirubicin, S-1 | Jinling Hospital, China | Stomach Neoplasms, Gastric Cancer | 05/19 | 10/23 | | |
PRODIGE 23, NCT01804790: Efficacy of Neoadjuvant Folfirinox Regimen in Patients With Resectable Locally Advanced Rectal Cancer |
|
|
| Active, not recruiting | 3 | 461 | Europe | mFolfirinox, Radiotherapy 50 Gy, Capecitabine, TME surgery, mFolfox6 or capecitabine | UNICANCER | Cancer of the Rectum | 09/19 | 05/25 | | |
2019-001364-30: Randomized phase 3 trial comparing FOLFOX to gemcitabine in metastatic first-line in patients with pancreatic adenocarcinoma and non-fit for FOLFIRINOX |
|
|
| Not yet recruiting | 3 | 400 | Europe | Oxaliplatin, Folinic acid, 5-Fluorouracil, Gemcitabine, Solution for infusion, Powder for solution for infusion | Assistance Publique- Hôpitaux de Paris | Diseases [C] - Cancer [C04] | | | | |
| Active, not recruiting | 3 | 2000 | Europe | FOLFOX regimen, folinic acid, infusional fluorouracil, and oxaliplatin, CAPOX, capecitabine plus oxaliplatin; XELOX | GERCOR - Multidisciplinary Oncology Cooperative Group | Colorectal Cancer | 01/20 | 12/23 | | |
NCT03431428: Comparison of Short-term Efficacy and Long-term Prognosis for Reduction Surgery and Radical Resection in Almost-cCR Rectal Cancer Patients |
|
|
| Recruiting | 3 | 477 | RoW | transanal surgery, Miles surgery, Preoperative chemoradiotherapy | Zhang Rui | Almost-cCR, Surgery, Rectal Cancer | 01/20 | 12/22 | | |
2018-001728-20: Neoadjuvant Radiochemotherapy versus Chemotherapy for Patients with Locally Advanced, Potentially Resectable Adenocarcinoma of the Gastroesophageal Junction (GEJ). Neoadjuvante Radiochemotherapie versus Chemotherapie für Patienten mit lokal fortgeschrittenem, potentiell resektablen Adenokarzinom des ösophagogastralen Übergangs. |
|
|
| Not yet recruiting | 3 | 340 | Europe | 5-Fluorouracil, Calcium Folinate, Oxaliplatin, Docetaxel, Solution for injection, Solution for solution for injection | Ruprecht-Karls-Universität Heidelberg, Deutsche Krebshilfe | Locally Advanced, Potentially Resectable Adenocarcinoma of the Gastroesophageal Junction (GEJ), Locally advanced resectable gastric cancer, Diseases [C] - Cancer [C04] | | | | |
2018-000876-14: ACO/ARO/AIO-18.1: Short-course radiotherapy versus chemoradiotherapy, followed by consolidation chemotherapy, and selective organ preservation for MRI-defined intermediate and high-risk rectal cancer patients A randomized phase III trial of the German Rectal Cancer Study Group |
|
|
| Not yet recruiting | 3 | 702 | Europe | 5-fluorouracil, Oxaliplatin, Capecitabine, folinic acid, Solution for infusion, Concentrate for solution for infusion, Tablet | University Hospital Frankfurt, Goethe University, German Cancer Aid | Locally advanced rectal cancer (UICC stage II and III), Rectal cancer, Diseases [C] - Cancer [C04] | | | | |
CALGB, NCT01150045: Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery |
|
|
| Active, not recruiting | 3 | 2527 | Canada, US | celecoxib, 5-fluorouracil, placebo, oxaliplatin, leucovorin | Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI) | Colorectal Cancer | 02/20 | | | |
| Active, not recruiting | 3 | 920 | Europe, US | M1 scheme, standard long course chemoradiotherapy | University Medical Center Groningen, Karolinska University Hospital, Leiden University Medical Center, Uppsala University Hospital, Dutch Cancer Society | Rectal Cancer | 03/20 | 12/26 | | |
NCT03511963: A Clinical Study to Compare the Efficacy, Safety and Immunogenicity of HLX04 and Bevacizumab Combined XELOX or mFOLFOX6 in the First-line Treatment of mCRC |
|
|
| Active, not recruiting | 3 | 677 | RoW | HLX04 100 mg in 4 ml Injection, Avastin 100 mg in 4 ml Injection | Shanghai Henlius Biotech | Metastatic Colorectal Cancer (mCRC) | 04/20 | 04/24 | | |
2020-000149-15: Combined chemotherapy and radiotherapy followed by planned surgery compared to combined chemotherapy and radiotherapy with surgery only when really needed, for patients with cancer in the esophagus. |
|
|
| Not yet recruiting | 3 | 1020 | Europe | Carboplatin, Paklitaxel, Cisplatin, 5-fluorouracil, Oxaliplatin, Calcium folinate, Concentrate for solution for infusion, Concentrate and solvent for solution for infusion, Solution for injection/infusion | Karolinska University Hospital, Karolinska University Hospital, Swedish Research Council | Resectable locally advanced squamous cell carcinoma (SCC) of the esophagus, Cancer in the gullet (esophagus), which is possible to operate., Diseases [C] - Cancer [C04] | | | | |
| Active, not recruiting | 3 | 2031 | Europe, Canada, Japan, US, RoW | Nivolumab, Opdivo, BMS-936558, Ipilimumab, Yervoy, BMS-734016, Oxaliplatin, Capecitabine, Leucovorin, Fluorouracil | Bristol-Myers Squibb, Ono Pharmaceutical Co. Ltd | Gastric Cancer, Gastroesophageal Junction Cancer, Esophageal Adenocarcinoma | 05/20 | 05/24 | | |
|
|
|
|
|
|
2020-002141-42: Addition of induction chemotherapy to the neoadjuvant treatment of patients with locally recurrent rectal cancer - the PelvEx II study Toevoeging van inductie chemotherapie aan de voorbehandeling van patiënten met lokaal teruggekeerde endeldarmkanker - de PelvEx II studie |
|
|
| Not yet recruiting | 3 | 364 | Europe | Capecitabine Accord, Oxaliplatin Accord, 5-Fluorouracil, Leucovorine Sandoz, Irinotecan, Infusion, Tablet, Oxaliplatin, Capecitabine, 5-fluorouracil, Leucovorin, Irinotecan | Catharina Hospital, Instituto Português de Oncologia de Lisboa Francisco Gentil – EPE, Catharina Ziekenhuis Eindhoven, ZonMW, ZonMw, Catharina Ziekenhuis Eindhoven | Locally recurrent rectal cancer Lokaal recidief rectum carcinoom, Locally recurrent rectal cancer Lokaal teruggekeerde endeldarmkanker, Diseases [C] - Cancer [C04] | | | | |
2017-003832-35: Preventive HIPEC in combination with perioperative FLOT versus FLOT alone for resectable diffuse type gastric and gastroesophageal junction Type II/III adenocarcinoma – The phase III “PREVENT” trial of the AIO /CAOGI /ACO |
|
|
| Not yet recruiting | 3 | 200 | Europe | Docetaxel, Oxaliplatin, 5-fluorouracil, Leucovorin, Cisplatin, Concentrate for solution for infusion, Solution for injection | Institute of Clinical Cancer Research (IKF) Krankenhaus Nordwest, Deutsche Krebshilfe | locally advanced resectable diffuse type adenocarcinoma of the oesophagogastric junction or the stomach, locally advanced resectable diffuse type gastric cancer, Diseases [C] - Cancer [C04] | | | | |
2018-001356-35: FOLFOX before surgey compared to risk-adapted chemotherapy after surgery in patients with locally advanced rectal cancer and low risk for local failure |
|
|
| Not yet recruiting | 3 | 550 | Europe | 5-Fluorouracil, Oxaliplatin, Leucovorin, Capecitabin, Solution for injection, Concentrate and solvent for solution for infusion, Tablet, Oxaliplatin, Leucovorin, Capecitabin | University of Heidelberg, German Cancer Aid | Locally advanced rectal adenocarcinoma localized 0 - 16 cm from the anal verge with low risk of local failure, Locally advanced rectal cancer with low risk of local failure, Diseases [C] - Cancer [C04] | | | | |
| Active, not recruiting | 3 | 214 | RoW | Hepatic arterial infusion chemotherapy, Transarterial chemoembolization, TACE regimen, HAIC Regimen, Oral Sorafenib | Sun Yat-sen University | Hepatocellular Carcinoma | 10/20 | 06/22 | | |
2016-002393-12: Systemic oxaliplatin or in intra-arterial chemotherapy combined with LV5FU2 ± Irinotecan, and targeted therapy, in first-line treatment of metastatic colorectal cancer restricted to the liver Chimiothérapie par oxaliplatine en intra-veineux ou dans le foie combiné à une chimiothérapie par LV5FU2 ± Irinotécan, et une thérapie ciblée, en intraveineux chez des patients ayant un cancer colorectal métastatique limité au foie. |
|
|
| Not yet recruiting | 3 | 348 | Europe | Solution for infusion, ELOXATINE | Fédération Francophone de Cancérologie Digestive, AMGEN | colorectal cancer with hepatic metastasis Cancer colorectal métastatique au niveau hépatique, colon cancer and rectal cancer with liver metastasis cancer du côlon ou du rectum avec métastases au niveau du foie, Diseases [C] - Cancer [C04] | | | | |
SONCAR, NCT02031939: Randomized Controlled Study on Optimize Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer |
|
|
| Active, not recruiting | 3 | 556 | RoW | Induction chemotherapy, Chemoradiotherapy and gap chemotherapy (Capecitabine combine with oxaliplatin), standard chemoradiotherapy | Sun Yat-sen University | Advanced Rectal Cancer | 12/20 | 12/25 | | |
| Recruiting | 3 | 570 | RoW | KL-140, Placebo | Sichuan Kelun Pharmaceutical Research Institute Co., Ltd. | Metastatic Colorectal Cancer | 12/20 | 12/23 | | |
NCT03415763: Adjuvant Chemotherapy in Patients With Clinical Stage III Rectal Cancer Undergoing Neoadjuvant Chemoradiotherapy |
|
|
| Recruiting | 3 | 764 | RoW | Capecitabine, Xeloda, mFOLFOX6 or CAPOX, 5-Fu-leucovorin-oxaliplatin or xeloda-oxaliplatin | LI XIN-XIANG | Rectal Neoplasms | 12/20 | 12/25 | | |
NCT03355612: XELOX Plus Apatinib vs XELOX as Post-operative Chemotherapy in Locally Advanced Gastric Signet Ring Carcinoma |
|
|
| Not yet recruiting | 3 | 456 | NA | Apatinib, YN968D1, XELOX, Capecitabine and Oxaliplatin | Tianjin Medical University Cancer Institute and Hospital | Gastric Carcinoma | 12/20 | 12/25 | | |
NCT03448549: SOX Versus XELOX as Adjuvant Chemotherapy for Stage III Colorectal Cancer Patients |
|
|
| Recruiting | 3 | 1191 | RoW | Oxaliplatin, Tegafur，gimeracil and oteracil potassium, Xeloda, Capecitabine | Peking University Cancer Hospital & Institute, Peking Union Medical College Hospital, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Peking University People's Hospital | Colorectal Cancer Stage III, Adjuvant Chemotherapy | 01/21 | 01/24 | | |
2020-000241-14: Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (LOTIS-5) |
|
|
| Ongoing | 3 | 350 | Europe, RoW | Loncastuximab Tesirine, Rituximab, Gemcitabine, Oxaliplatin, ADCT-402, Powder for concentrate for solution for infusion, Concentrate for solution for infusion, Powder for solution for infusion, TRUXIMA, Bendacitabin 38 mg/ml, Oxali-Bendalis 5 mg/ml | ADC Therapeutics SA, ADC THERAPEUTICS SA, ADC Therapeutics SA | Diffuse Large B-Cell Lymphoma (DLBCL), Lymphoma, Diseases [C] - Cancer [C04] | | | | |
| Completed | 3 | 830 | Europe | Induction chemotherapy with gemcitabine or FOLFIRINOX, all brands of gemcitabine and FOLFIRINOX components are allowed, Radiotherapy, 28 x 1.8 Gy, Chemotherapy, gemcitabine, all brands of gemcitabine are allowed, Chemotherapy with gemcitabine or FOLFIRINOX according to induction chemotherapy | University of Erlangen-Nürnberg Medical School | Pancreatic Cancer | 02/21 | 11/23 | | |
KEYNOTE-177, NCT02563002 / 2015-002024-89: Study of Pembrolizumab (MK-3475) vs Standard Therapy in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (MK-3475-177/) |
|
|
| Completed | 3 | 307 | NA | mFOLFOX6, FOLFIRI, Pembrolizumab, MK-3475, SCH 900475, KEYTRUDA®, Bevacizumab, Cetuximab | Merck Sharp & Dohme LLC | Colorectal Carcinoma | 02/21 | 07/23 | | |
|
|
|
|
|
CONVERT, NCT02288195: Neoadjuvant Chemotherapy Alone Versus Preoperative Chemoradiation for Locally Advanced Rectal Cancer Patients |
|
|
| Active, not recruiting | 3 | 663 | RoW | Oxaliplatin, Eloxatin, capecitabine, Xeloda, Radiation, radiotherapy | Sun Yat-sen University, Shantou Central Hospital, Liaoning Tumor Hospital & Institute, The First Affiliated Hospital with Nanjing Medical University, Fujian Cancer Hospital, Guangdong Provincial Hospital of Traditional Chinese Medicine, First Affiliated Hospital of Chongqing Medical University, The First Affiliated Hospital of Guangzhou Medical University, Guangdong Provincial People's Hospital, Cancer Hospital of Guangxi Medical University, Meizhou People's Hospital, Henan Cancer Hospital, Affiliated Cancer Hospital of Shantou University Medical College, Hubei Cancer Hospital, First Affiliated Hospital of Kunming Medical University, Longyan City First Hospital, Shengjing Hospital, Zhejiang Cancer Hospital, Jiangmen Central Hospital, West China Hospital, The Third Affiliated Hospital of Kunming Medical College. | Rectal Neoplasms | 03/21 | 03/24 | | |
2019-004582-40: TIming of start of systemIc treatment for asymptomatic MEtastasized PANcreatic cancer |
|
|
| Ongoing | 3 | 184 | Europe | Oxaliplatin, Leucovorin, Irinotecan, Fluorouracil, Paclitaxel, Gemcitabine, Concentrate for solution for infusion | Amsterdam UMC-Location AMC-dept. Internal Medicin, University of Amsterdam | Metastasized pancreatic cancer Gemetastaseerd pancreas carcinoom, Metastasized pancreatic cancer Uitgezaaide alvleesklierkanker, Diseases [C] - Cancer [C04] | | | | |
OPTICAL, NCT02572141: FOLFOX or CAPOX Perioperative Chemotherapy Versus Postoperative Chemotherapy for Locally Advanced Colon Cancer |
|
|
| Active, not recruiting | 3 | 738 | RoW | Perioperative chemotherapy with mFOLFOX6 or CAPOX regimens, Oxaliplatin, 5-Fluorouracil, Capecitabine, Leucovorin, Postoperative chemotherapy with mFOLFOX6 or CAPOX regimens | Sun Yat-sen University | Colon Cancer | 04/21 | 04/23 | | |
TNTCRT, NCT03177382: Total Neoadjuvant Treatment vs. Chemoradiotherapy in Local Advanced Rectal Cancer With High Risk Factors |
|
|
| Recruiting | 3 | 458 | RoW | Total neoadjuvant treatment, TNT, concurrent chemoradiotherapy, CRT, TME, Adjuvant chemotherapy | West China Hospital | Total Neoadjuvant Treatment, Chemoradiotherapy, Local Advanced Rectal Cancer, High Risk Factors | 05/21 | 05/23 | | |
| Active, not recruiting | 3 | 464 | Europe, RoW | FOLFIRI-cetuximab, mFOLFOX6-bevacizumab, OPTIMOX-bevacizumab, irinotecan-based chemo + bevacizumab, Anti-EGFR agent (cetuximab +/- irinotecan or panitumumab), XELOX + bevacizumab | GERCOR - Multidisciplinary Oncology Cooperative Group, Hoffmann-La Roche | Colorectal Cancer Metastatic | 07/23 | 12/24 | | |
ORIENT-16, NCT03745170: Efficacy and Safety Evaluation of Sintilimab or Placebo in Combination With XELOX as First Line Treatment in Patients With Gastric Cancer |
|
|
| Completed | 3 | 650 | RoW | Sintilimab, IBI308, Oxaliplatin, Capecitabine, placebo | Innovent Biologics (Suzhou) Co. Ltd. | Gastric Cancer | 06/21 | 10/22 | | |
|
2020-005141-16: Chemotherapy before or after surgery in patients with resectable pancreatic cancer: the PREOPANC-3 study. |
|
|
| Not yet recruiting | 3 | 378 | Europe | Leucovorin calcium, Fluorouracil, Irinotecan, Oxaliplatin, Powder for solution for injection/infusion, Solution for infusion, Concentrate for solution for infusion, LEUCOVORIN CALCIUM, Fluorouracil, Irinotecan, Oxaliplatin | Erasmus MC, Erasmus MC | non-metastatic resectable pancreatic cancer, non-metastatic resectable pancreatic cancer, Diseases [C] - Cancer [C04] | | | | |
EPAC1, NCT03199989: Efficacy of Postoperative Adjuvant Chemotherapy for Stage II Colon Cancer With High Risk Factors |
|
|
| Recruiting | 3 | 1254 | RoW | CapeOX（Capecitabine+Oxaliplatin）, Observation | Peking University Cancer Hospital & Institute, Peking Union Medical College Hospital, Peking University People's Hospital | Adjuvant Chemotherapy | 07/21 | 07/24 | | |
2021-000317-17: Survival analysis after pre-surgical therapy in patients with resectable pancreatic cancer and risk factors ANÁLISIS DE SUPERVIVENCIA TRAS TRATAMIENTO ANTES DE LA CIRUGÍA EN CÁNCER DE PÁNCREAS RESECABLE CON FACTORES DE RIESGO |
|
|
| Ongoing | 3 | 116 | Europe | Irinotecan, Fluorouracil, Oxaliplatin, calcium folinate, Concentrate for solution for injection/infusion, Solution for infusion | Fundación para la Gestión de la Investigación Biomédica de Cádiz-INIBICA, Instituto de Salud Carlos III | Resectable pancreatic cancer and risk factors Cáncer de pancreas resecable con factores de riesgo, Non-operable pancreatic cancer plus other conditions that increase the possibility to adquire a disease Cancer de pancreas no operable mas otras condiciones que aumenten la posibilidad de adquirir una enfermedad, Diseases [C] - Cancer [C04] | | | | |
2020-006144-18: Prospective, randomized, open, multicenter Phase III trial to investigate the efficacy of active post-resection/ablation therapy in patients with metastatic colorectal cancer Prospektive, randomisierte, offene, multizentrische Phase III Studie zur Untersuchung der Wirksamkeit einer Therapie in Patienten mit metastasiertem kolorektalen Karzinom, nach erfolgter Resektion oder Ablation |
|
|
| Not yet recruiting | 3 | 507 | Europe | 5-Fluorouracil, Oxaliplatin, Leucovorin, Irinotecan, Solution for solution for injection, Concentrate and solvent for solution for infusion, Solution for injection, Concentrate for solution for infusion, Oxaliplatin, Leucovorin | Charité Universitätsmedizin Berlin, DFG - Deutsche Forschungsgemeinschaft e.V. | Metastatic colorectal cancer after definite interventional therapy of all lesions, Metastatic colorectal cancer after therapy of lesions, Diseases [C] - Cancer [C04] | | | | |
2020-004906-79: A study to evaluate the efficacy of oxaliplatin- or gemcitabine-based chemotherapy after allocation by standard criteria or by genetic markers in patients with resected pancreatic carcinoma Studie zur Wirksamkeit einer Chemotherapie nach Operation beim Karzinom der Bauchspeicheldrüse, wobei die Zuteilung zur Oxaliplatin-basierten oder Gemcitabin-basierten Chemotherapie entweder nach klinischen Standardkriterien oder nach genetischen Markern erfolgt |
|
|
| Not yet recruiting | 3 | 394 | Europe | Gemcitabine, Capecitabine, 5-fluorouracil, Irinotecan, Calcium Folinate, Oxaliplatin, Powder for solution for infusion, Film-coated tablet, Solution for injection, Concentrate for solution for infusion, Solution for injection/infusion | Ruprecht-Karls-University Heidelberg, Medical Faculty represented by Universitätsklinikum Heidelberg, Dietmar Hopp Stiftung, Cancerforskningsfonden i Norrland | Resected pancreatic ductal adenocarcinoma operiertes duktales Pankreas-Adenokarzinom, Resected pancreatic ductal adenocarcinoma operiertes duktales Bauchspeicheldrüsen-Adenokarzinom, Diseases [C] - Cancer [C04] | | | | |
APEC, NCT02965248: Adjuvant Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Versus no HIPEC in Locally Advanced Colorectal Cancer ( Study) |
|
|
| Recruiting | 3 | 147 | RoW | Standard adjuvant systemic chemotherapy, adjuvant oxaliplatin, 5-FU, and leucovorin calcium (mFOLFOX6), adjuvant oxaliplatin and capecitabine (CapeOx), adjuvant 5-FU and leucovorin calcium (sLV5FU2), adjuvant capecitabine (Cape), Hyperthermic intraperitoneal chemotherapy (HIPEC) with raltitrexed, Intraperitoneal raltitrexed 3 mg/m2, Hyperthermic intraperitoneal chemotherapy (HIPEC) with oxaliplatin, I.V. leucovorin calcium 20 mg/m2, I.V. 5-FU 400 mg/m2, Intraperitoneal oxaliplatin 130 mg/m2 | Fudan University | Locally Advanced Colorectal Cancer | 11/21 | 11/23 | | |
NCT02087475: Perioperative FOLFIRI VS Adjuvant FOLFIRI in Resectable Advanced CRC Failed to Oxaliplatin |
|
|
| Recruiting | 3 | 360 | RoW | Irinotecan, 5-fluorouracil, Local radiotherapy, R0 resection | Sixth Affiliated Hospital, Sun Yat-sen University | Colorectal Neoplasms, Effects of Chemotherapy, Surgery, Metastasis, Local Neoplasm Recurrence | 12/21 | 12/24 | | |
ARMANI, NCT02934464: Assessment of Ramucirumab Plus Paclitaxel as Switch MANteInance Versus Continuation of First-line Chemotherapy in Patients With Advanced HER-2 Negative Gastric or Gastroesophageal Junction Cancers |
|
|
| Recruiting | 3 | 280 | Europe | RAMUCIRUMAB, Cyramza, Paclitaxel, FOLFOX 4, Oxaliplatino + l-leucovorin + 5 Fluorouracile, mFOLFOX 6, XELOX, Oxaliplatino + Capecitabina | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | Stomach Neoplasms | 12/21 | 12/21 | | |
NCT03788226: A Randomized Phase III Study Comparing POF With SOX/CAPOX/FOLFOX as a Postoperative Adjuvant Chemotherapy for Curatively Resected Stage III Gastric Cancer |
|
|
| Recruiting | 3 | 600 | RoW | POF, CAPOX/SOX/FOLFOX | Fujian Cancer Hospital | Gastric Cancer Stage III | 12/21 | 12/23 | | |
NCT04303429: Adjuvant Chemotherapy in High Risk Stage II Colon Cancer |
|
|
| Not yet recruiting | 3 | 962 | NA | FOLFOX/XELOX/Capecitabine | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Stage II Colon Cancer, Adjuvant Chemotherapy | 01/22 | 01/25 | | |
| Completed | 3 | 171 | Europe | Gemcitabine, Folinic Acid, 5-Fluoro-uracil, Oxaliplatin, Irinotecan, L-folinic | UNICANCER | Pancreatic Cancer, Carcinoma | 02/22 | 09/23 | | |
NCT03813784: A Study to Evaluate SHR-1210 in Combination With Capecitabine + Oxaliplatin Sequenced by SHR-1210 + Apatinib as First-line Therapy in Treatment of Advanced Gastric Cancer |
|
|
| Active, not recruiting | 3 | 887 | RoW | SHR-1210, Capecitabine, Oxaliplatin, Apatinib | Jiangsu HengRui Medicine Co., Ltd. | Gastric Cancer, GastroEsophageal Cancer | 02/22 | 03/23 | | |
RESCUE-GC, NCT02867839: Adjuvant Chemotherapy With S-1 Plus Oxaliplatin Versus S-1 Alone in Locally Advanced Gastric Cancer |
|
|
| Recruiting | 3 | 564 | RoW | Oxaliplatin plus S-1, SOX, S-1 only, S-1 | Peking University Cancer Hospital & Institute | Gastric Cancer | 02/22 | 02/24 | | |
| Active, not recruiting | 3 | 649 | Europe, Japan, US, RoW | Cisplatin, Oxaliplatin, Fluorouracil (5-FU), Capecitabine, Paclitaxel, Tislelizumab, BGB-A317, Placebo | BeiGene | Esophageal Squamous Cell Carcinoma (ESCC) | 02/22 | 08/24 | | |
|
|
|
NCT04809142: A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule as Second-line Treatment in Subjects With Advanced Biliary Cancer |
|
|
| Recruiting | 3 | 392 | RoW | TQB2450 Injection, Anlotinib hydrochloride, Oxaliplatin injection, Capecitabine tablets, Gemcitabine hydrochloride injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Biliary Cancer | 03/22 | 02/23 | | |
NCT03125980: Perioperative Versus Postoperative CapOX Chemotherapy for Locally Advanced Colon Cancer |
|
|
| Recruiting | 3 | 1370 | RoW | capecitabine plus oxaliplatin before and after surgery, capecitabine plus oxaliplatin after surgery | Fudan University | Locally Advanced Colon Cancer | 05/22 | 05/27 | | |
CAIRO4, NCT01606098: The Role of Surgery of the Primary Tumour in Patients With Synchronous Unresectable Metastases of Colorectal Cancer |
|
|
| Completed | 3 | 206 | Europe | Surgery of the primary tumour, Systemic treatment, Bevacizumab in combination with fluoropyrimidine-based schedules | Dutch Colorectal Cancer Group, Hoffmann-La Roche | Colon Cancer, Primary Tumour, Rectal Cancer | 06/22 | 12/22 | | |
GRECCAR12, NCT02514278: Optimisation of Response for Organ Preservation in Rectal Cancer : Neoadjuvant Chemotherapy and Radiochemotherapy vs. Radiochemotherapy |
|
|
| Active, not recruiting | 3 | 218 | Europe | Neoadjuvant chemotherapy Folfirinox, 4 cycles, 50 Gy, 2 Gy/session; 25 fractions, Local excision in good responders, Rectal excision in bad responders, Capecitabine | University Hospital, Bordeaux | Rectal Cancer | 06/22 | 06/24 | | |
ChiCTR2000034867: A multicenter, randomized, double-blind, placebo-controlled phase III clinical study on the prevention of peripheral neurotoxicity of oxaliplatin by yiqiwenjing recipe |
|
|
| Not yet recruiting | 3 | 360 | | Oxaliplatin containing chemotherapy combined with placebo ;Adjuvant chemotherapy combined with yiqiwenjing prescription I called Huangqi Guizhi Wuwu granules. ;Adjuvant chemotherapy combined with yiqiwenjing prescription II called Danggui Sini granules. | Jiangsu Province Hospital on Integration Chinese and Western Medicine; Jiangsu Province Hospital on Integration Chinese and Western Medicine, Jiangsu Provincial Department of science and technology, provincial key research and development program (Social Development) project: No:BE2019767 | Peripheral neurotoxicity of oxaliplatin | | | | |
YWPPEOPNCT, NCT04690283: Yiqi Wenjing Prescriptions Preventive Efficacy of Oxaliplatin-induced Peripheral Neuropathy Clinical Trial |
|
|
| Not yet recruiting | 3 | 360 | NA | Mimetic granules of Yiqi-Wenjing prescriptions, Mimetic granules of Huangqi-Guizhi-Wuwu plus Danggui-Sini decoction, Huangqi-Guizhi-Wuwu granules, Danggui-Sini granules | Nanjing NingQi Medicine Science and Technology Co., Ltd., Jiangsu Provincial Hospital of Integrated Traditional Chinese and Western Medicine, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, The First Affiliated Hospital with Nanjing Medical University, Jiangsu Cancer Institute & Hospital, Fudan University | Chemotherapy-induced Peripheral Neuropathy, Colorectal Cancer | 07/22 | 10/22 | | |
UNION, NCT04928807: Short-Course Radiotherapy Followed by Neoadjuvant Chemotherapy and Camrelizumab in Locally Advanced Rectal Cancer |
|
|
| Active, not recruiting | 3 | 231 | RoW | Short course radiotherapy sequential camrelizumab and chemotherapy | Wuhan Union Hospital, China, Jiangsu HengRui Medicine Co., Ltd. | Rectal Cancer | 03/23 | 03/26 | | |
| Recruiting | 3 | 564 | Europe | FOLFOX/ FOLFIRI with bevacizumab, - bevacizumab, - irinotecan, - leucovorin, - 5-fluorouracil, - oxaliplatin, FOLFOXIRI with bevacizumab, FOLFOX/ FOLFIRI with panitumumab, - panitumumab | Dutch Colorectal Cancer Group | Colorectal Cancer, Liver Metastases | 08/22 | 07/25 | | |
KL140-Ⅲ-02-CTP, NCT04835142: Comparison of A140 and Erbitux Combined With mfolfox6 to Evaluate Efficacy and Safety of First-line Treatment for Ras Wild-type mCRC |
|
|
| Recruiting | 3 | 686 | RoW | Double blind control period A140, KL-140, Open single period A140 | Sichuan Kelun Pharmaceutical Research Institute Co., Ltd. | Metastatic Colorectal Cancer | 08/22 | 04/23 | | |
NCT03851913: The Impact on Survival of Neo-adjuvant Transarterial Chemoinfusion (TAI) for Patients With Beyond Milan Criteria BCLC Stage A/B Hepatocellular Carcinoma Who Underwent Hepatectomy |
|
|
| Recruiting | 3 | 344 | RoW | TAI | Sun Yat-sen University | Hepatocellular Carcinoma | 08/22 | 08/24 | | |
NCT04516681: IV Ascorbic Acid in Peritoneal Metastatic Colorectal Cancer |
|
|
| Recruiting | 3 | 400 | RoW | Ascorbic acid, Vitamin C, FOLFOXIRI Protocol, FOLFOXIRI+/- bevacizumab | Fudan University | Colorectal Cancer, Vitamin C, GLUT3 | 09/22 | 09/23 | | |
NCT03961867: Docetaxel Versus Oxaliplatin as Addition to S-1 for Stage II / III Gastric Adenocarcinoma |
|
|
| Recruiting | 3 | 440 | RoW | Docetaxel, S-1, Oxaliplatin | Sixth Affiliated Hospital, Sun Yat-sen University | Gastric Cancer | 09/22 | 09/25 | | |
NCT04384601: Dragon III-Phase 3: Neoadjuvant Chemotherapy (FLOT Versus SOX) for Gastric Cancer |
|
|
| Not yet recruiting | 3 | 246 | RoW | Chemotherapy, FLOT chemotherapy, SOX chemotherapy | Ruijin Hospital | Gastric Cancer, Neoadjuvant Chemotherapy | 09/22 | 09/27 | | |
Spotlight, NCT03504397 / 2017-002567-17: A Phase 3 Efficacy, Safety and Tolerability Study of Zolbetuximab (Experimental Drug) Plus mFOLFOX6 Chemotherapy Compared to Placebo Plus mFOLFOX6 as Treatment for Gastric and Gastroesophageal Junction (GEJ) Cancer |
|
|
| Active, not recruiting | 3 | 566 | Europe, Canada, Japan, US, RoW | zolbetuximab, IMAB362, placebo, oxaliplatin, folinic acid, fluorouracil | Astellas Pharma Global Development, Inc. | Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma | 09/22 | 03/25 | | |
|
CRTCOESC, NCT02025036: Chemoradiotherapy of Capecitabine With or Without Oxaliplatin Versus Cisplatin-5-FU for Esophageal Squamous Cancer |
|
|
| Active, not recruiting | 3 | 249 | RoW | Capecitabine(Aibin), Aibin, Oxaliplatin(Aiheng), Aiheng, Radiotherapy, Radiation Therapy | The First Affiliated Hospital of Henan University of Science and Technology, Luoyang Central Hospital, Military 150 Hospital, Anyang Cancer Hospital, Nanyang Central Hospital, Henan Oncology Hospital, The First Affiliated Hospital of Xinyang Medical College, Sanmenxia Central Hospital | Stage III Esophageal Squamous Cell Carcinoma, Stage II Esophageal Squamous Cell Carcinoma | 09/22 | 04/25 | | |
NCT06190782: Local Therapy for Oligometastatic ESCC Patients Treated With PD-1 Inhibitor |
|
|
| Recruiting | 3 | 354 | RoW | PD-1 inhibitor+/- chemotherapy combined with local therapy, systemic therapy alone, the systemic therapy only | Fudan University | Esophageal Squamous Cell Carcinoma, Oligometastatic Disease, Radiotherapy | 09/25 | 09/27 | | |
| Active, not recruiting | 3 | 1579 | Europe, Canada, Japan, US, RoW | Pembrolizumab, KEYTRUDA®, MK-3475, Cisplatin, PLATINOL®, 5-fluorouracil, ADRUCIL®, 5FU, oxaliplatin, ELOXATIN®, capecitabine, XELODA®, Placebo for Pembrolizumab | Merck Sharp & Dohme LLC | Stomach Neoplasms | 10/22 | 03/25 | | |
|
GLOW, NCT03653507 / 2018-000519-26: A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma |
|
|
| Active, not recruiting | 3 | 507 | Europe, Canada, Japan, US, RoW | zolbetuximab, IMAB362, oxaliplatin, capecitabine, placebo | Astellas Pharma Global Development, Inc. | Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma | 10/22 | 03/25 | | |
|
NCT03678428: FUDR/Oxaliplatin HAI Plus Irinotecan vs. FOLFOXIRI Chemotherapy in Treating Initially Unresectable CRCLM |
|
|
| Terminated | 3 | 92 | RoW | Irinotecan, Oxaliplatin HAI, Floxuridine, Leucovorin, 5-FU, Oxaliplatin | Sun Yat-sen University | Metastatic Colorectal Cancer, Liver Metastases | 10/22 | 12/22 | | |
NCT03399253: Chemotherapy Alone Versus Surgery Plus Chemotherapy for Distal Gastric Cancer With One Non-curable Factor |
|
|
| Recruiting | 3 | 120 | RoW | surgery, chemotherapy, XELOX | Sun Yat-sen University | Gastric Cancer | 11/22 | 12/25 | | |
AGENT, NCT03750786 / 2017-004154-41: A Study to Compare the Efficacy of Arfolitixorin Versus Leucovorin in Combination With 5 Fluorouracil, Oxaliplatin, and Bevacizumab in Patients With Advanced Colorectal Cancer |
|
|
| Completed | 3 | 490 | Europe, Canada, Japan, US, RoW | Arfolitixorin, Leucovorin | Isofol Medical AB | Colo-rectal Cancer | 11/22 | 11/22 | | |
NCT03399110: XELOX for 4 Months Versus 6 Months in Gastric Cancer (LOMAC) |
|
|
| Active, not recruiting | 3 | 1032 | RoW | Oxaliplatin, Eloxatin, Capecitabine, Xeloda | Fudan University | Gastric Cancer | 08/26 | 08/26 | | |
NCT04667351: HAIC of Oxaliplatin, and 2400 mg/m² 5-fu vs HAIC of Oxaliplatin, and 1200 mg/m² 5-fu for Unresectable HCC: a Randomised Phase 3 Non-inferiority Trial |
|
|
| Recruiting | 3 | 400 | RoW | 2400 mg/m² 5-fu, 1200 mg/m² 5-fu | Sun Yat-sen University, Kaiping Central Hospital, Guangzhou No.12 People's Hospital | HepatoCellular Carcinoma | 12/22 | 12/22 | | |
NCT04687163: Sorafenib or Lenvatinib Plus HAIC of 130 mg/m² Oxaliplatin, and 5-fu vs Sorafenib or Lenvatinib Plus HAIC of 85mg/m² Oxaliplatin, and 5-fu for Unresectable Advanced HCC: a Randomised Phase 3 Trial |
|
|
| Recruiting | 3 | 400 | RoW | HAIC of 130 mg/m² Oxaliplatin, and 5-fu, HAIC of 85 mg/m² Oxaliplatin, and 5-fu, TKI | Sun Yat-sen University, Kaiping Central Hospital, Guangzhou No.12 People's Hospital | Hepatocellular Carcinoma | 12/22 | 12/22 | | |
RESONANCE-II, NCT04483076: Oxaliplatin Combined With S-1(SOX) Neoadjuvant Chemotherapy for Different Cycles in Patients With Gastric Cancer |
|
|
| Recruiting | 3 | 524 | RoW | Chemotherapy drug, Gastrectomy, Laparoscopic exploration | Chinese PLA General Hospital | Gastric Cancer, Chemotherapy Effect | 12/22 | 12/28 | | |
NCT03365765: mFOLFOX6 Chemotherapy With Apatinib as Postoperative Treatment in Stage IIIB or IIIC Colorectal Cancer |
|
|
| Completed | 3 | 63 | RoW | Apatinib, YN968D1, Oxaliplatin, Eloxatin, 5-fluorouracil, Adrucil, Carac, Efudex, Efudix | Huashan Hospital | Apatinib | 12/22 | 12/22 | | |
NCT04404491: Clinical Control Study of Immunotherapy and Concurrent Chemoradiotherapy in Patients With Esophageal Cancer Recurrence |
|
|
| Not yet recruiting | 3 | 240 | NA | Procedural death 1, Camrelizumab, Capecitabine, Aibin, Radiotherapy, Radiation Therapy, Placebo | The First Affiliated Hospital of Henan University of Science and Technology | Esophageal Malignant Neoplasm, Local Recurrence | 12/22 | 06/23 | | |
NCT02085655: PEG-ASP+Gemox Regimen and Thalidomide for NK/T Lymphoma |
|
|
| Recruiting | 3 | 264 | RoW | pegaspargase, Oncaspar, Gemcitabine, Gemzar, Oxaliplatin, Eloxatin, Methotrexate, Dexamethasone, Thalidomide | Huiqiang Huang, Sun Yat-sen University | Extranodal NK-T-Cell Lymphoma, Nasal and Nasal-Type | 12/22 | 12/22 | | |
NCT03192644: The Impact on Recurrence Risk of Adjuvant Transarterial Chemoinfusion (TAI) Versus Adjuvant Transarterial Chemoembolization (TACE) for Patients With Hepatocellular Carcinoma And Portal Vein Tumor Thrombosis (PVTT) After Hepatectomy : A Random, Controlled, Stage III Clinical Trial. |
|
|
| Recruiting | 3 | 162 | RoW | TAI, TACE, epidoxorubicin and cisplatin and lipiodol, mFOLFOX6 (oxaliplatin, calcium folinate, and 5-FU) | Sun Yat-sen University | Hepatocellular Carcinoma | 12/22 | 12/24 | | |
NCT03192618: The Impact on Recurrence Risk of Adjuvant Transarterial Chemoinfusion (TAI) for Patients With Hepatocellular Carcinoma And Microvascular Invasion (MVI) After Hepatectomy : A Random, Controlled, Stage III Clinical Trial. |
|
|
| Recruiting | 3 | 290 | RoW | adjuvant transarterial chemoinfusion (TAI), mFOLFOX6 (oxaliplatin, calcium folinate, and 5-FU) | Sun Yat-sen University | Hepatocellular Carcinoma | 12/22 | 12/24 | | |
GAPSO, NCT03801668: Albumin-bound Paclitaxel Plus S-1 Versus SOX as First-line Treatment in Advanced or Recurrent Gastric Adenocarcinoma |
|
|
| Recruiting | 3 | 294 | RoW | Albumin-bound Paclitaxel plus S-1, Oxaliplatin plus S-1 | Huazhong University of Science and Technology, CSPC Ouyi Pharmaceutical Co., Ltd. | Gastric Cancer | 12/22 | 03/23 | | |
NCT05362617: mFOLXOX6 Versus FOLFIRI for Colorectal Patients Recurrence After Oxaplatin Based Adjuvant Chemotherapy |
|
|
| Recruiting | 3 | 328 | RoW | FOLFIRI | Second Affiliated Hospital, School of Medicine, Zhejiang University | Metastatic Colorectal Cancer | 12/22 | 12/23 | | |
ZUMA-7, NCT03391466 / 2017-002261-22: Study of Effectiveness of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma |
|
|
| Active, not recruiting | 3 | 359 | Europe, Canada, US, RoW | Axicabtagene Ciloleucel, KTE-C19, axi-cel, Yescarta ®, Platinum-containing salvage chemotherapy (eg, R-ICE) followed by high dose therapy (eg, BEAM) and autologous stem cell transplant in responders., Cyclophosphamide, Fludarabine | Kite, A Gilead Company | Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | 03/21 | 10/24 | | |
|
|
|
|
|
|
|
NCT04675983: A Study of Sintilimab Plus Ramucirumab as First-line Treatment for G/EGJ Adenocarcinoma (ORIENT-106) |
|
|
| Terminated | 3 | 36 | RoW | Sintilimab, Tyvyt, IBI308, Ramucirumab, LY3009806, IMC-1121B, Cyramza, Cisplatin, 5-fluorouracil, Oxaliplatin, Capecitabine | Innovent Biologics (Suzhou) Co. Ltd. | Gastric Adenocarcinoma | 02/23 | 02/23 | | |
| Terminated | 3 | 326 | Europe, US, RoW | Trilaciclib, G1T28, CDK 4/6 inhibitor, Placebo | G1 Therapeutics, Inc. | Colorectal Cancer Metastatic, Myelosuppression-Adult, Chemotherapeutic Toxicity | 02/23 | 03/23 | | |
|
|
RATIONALE 305, NCT03777657 / 2018-000312-24: Tislelizumab in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Gastric, or Gastroesophageal Junction Carcinoma |
|
|
| Active, not recruiting | 3 | 997 | Europe, Japan, US, RoW | Tislelizumab, BGB-A317, Placebo, Cisplatin, Oxaliplatin, Capecitabine, 5-FU | BeiGene | Gastric, or Gastroesophageal Junction Adenocarcinoma | 02/23 | 12/24 | | |
|
|
|
NCT03469479: Neoadjuvant HAIC for Resectable Hepatocellular Carcinoma Beyond Milan Criteria |
|
|
| Recruiting | 3 | 252 | RoW | FOLFOX, Hepatic Arterial Infusion Chemotherapy of FOLFOX, Hepatic resection | Sun Yat-sen University | Hepatocellular Carcinoma | 03/23 | 03/23 | | |
| Completed | 3 | 800 | Japan, RoW | Nivolumab, BMS-936558, ONO-4538, MDX-1106, Tegafur-gimeracil-oteracil potassium, Oxaliplatin, Capecitabine, Placebo | Ono Pharmaceutical Co. Ltd, Bristol-Myers Squibb | Gastric Cancer | 08/22 | 03/23 | | |
|
| Active, not recruiting | 3 | 438 | Europe | 5-Fluorouracil, Leucovorin, Oxaliplatin, Docetaxel, Carboplatin, Paclitaxel, Neoadjuvant radiation | University Hospital Schleswig-Holstein, Clinical Trials Unit Freiburg, University of Freiburg, University of Leipzig, University of Luebeck, University of Hamburg-Eppendorf | Esophageal Adenocarcinoma (UICC TNM7), Adenocarcinoma of the Esophagogastric Junction | 05/24 | 12/24 | | |
GASTFOX, NCT03006432: PHASE III RANDOMISED TRIAL TO EVALUATE FOLFOX WITH OR WITHOUT DOCETAXEL (TFOX) AS 1st LINE CHEMOTHERAPY FOR LOCALLY ADVANCED OR METASTATIC OESOPHAGO-GASTRIC CARCINOMA |
|
|
| Active, not recruiting | 3 | 507 | Europe, RoW | Oxaliplatin, 5Fluorouracil bolus, 5Fluorouracil continu, Docetaxel, Folinic Acid | Federation Francophone de Cancerologie Digestive, UNICANCER, GERCOR - Multidisciplinary Oncology Cooperative Group | OESOPHAGO-GASTRIC CARCINOMA | 04/23 | 03/24 | | |
2022-002214-17: Repeat local treatment +/- neoadjuvant systemic therapy for recurrent colorectal liver metastases. Lokale behandeling +/- neoadjuvant systemische therapie voor recidieven van leveruitzaaiingen van dikke- en endeldarmkanker. |
|
|
| Ongoing | 3 | 360 | Europe | CAPOX (capecitabine with oxaliplatin) FOLFOX/FOLFIRI (5-fluorouracil/leucovorin with oxaliplatin or, Concentrate for solution for infusion, CAPOX (capecitabine with oxaliplatin) FOLFOX/FOLFIRI (5-fluorouracil/leucovorin with oxaliplatin or irinotecan) (with or without bevacizumab, per-patient based) | Amsterdam University Medical Centers, Amsterdam University Medical Centers | Recurrent colorectal liver metastases Recidief colorectale levermetastasen, Recurrent liver metastases from colorectal cancer Recidief lever uitzaaiingen van dikke- en endeldarmkanker, Diseases [C] - Cancer [C04] | | | | |
NCT03398291: Simultaneous Resection of Pancreatic Cancer and Liver Oligometastasis After Induction Chemotherapy |
|
|
| Recruiting | 3 | 300 | RoW | Synchronous resection of primary pancreatic cancer and liver oligometastasis, Standard chemotherapy | Fudan University | Pancreatic Cancer, Liver Metastases, Surgery | 06/23 | 06/25 | | |
CIRCULATE, NCT04089631: Circulating Tumour DNA Based Decision for Adjuvant Treatment in Colon Cancer Stage II Evaluation |
|
|
| Recruiting | 3 | 4812 | Europe | Capecitabine, Xeloda | Technische Universität Dresden | Colon Cancer Stage II | 06/23 | 06/26 | | |
NCT06172205: Infusional FOLFOX Plus Camrelizumab and Apatinib vs HAIC-FOLFOX Plus Camrelizumab and Apatinib for Advanced HCC |
|
|
| Recruiting | 3 | 192 | RoW | intravenous FOLFOX7 plus Camrelizumab and apatinib, HAIC-FOLFOX plus Camrelizumab and apatinib | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | BCLC Stage C Hepatocellular Carcinoma, Chemotherapy Effect | 07/26 | 07/27 | | |
| Completed | 3 | 479 | RoW | CS1001 monoclonal antibody, CS1001 placebo, Oxaliplatin, Capecitabine | CStone Pharmaceuticals | Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | 07/23 | 09/23 | | |
|
|
NCT05921942: The Impact of Metformin Administration on the Clinical Outcome of Stage IV Colon Cancer |
|
|
| Completed | 3 | 70 | RoW | Metformin | Ain Shams University | Colorectal Cancer | 12/22 | 12/22 | | |
| Recruiting | 3 | 600 | RoW | Short-course radiotherapy with neoadjuvant chemotherapy, Long-term chemoradiotherapy | Chinese Academy of Medical Sciences | Cancer, Rectum | 08/23 | 08/25 | | |
NCT03950154: Study of Chemotherapy Combination With Autologous Cell Immunotherapy in the Recurrent and Metastatic Colorectal Cancer |
|
|
| Recruiting | 3 | 198 | RoW | Bevacizumab Injection [Avastin], Avastin, Oxaliplatin, Capecitabine, PD1-T cells, PD-1 monoclonal antibody-activated peripheral blood T-lymphocyte | Tianjin Medical University Cancer Institute and Hospital | Colorectal Cancer | 08/23 | 08/23 | | |
NCT04342936: Study of Camrelizumab (SHR-1210) vs. Chemotherapy in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma |
|
|
| Recruiting | 3 | 56 | RoW | Camrelizumab, SHR-1210, Investigator's choice of Chemotherapy | Jiangsu HengRui Medicine Co., Ltd. | Classical Hodgkin Lymphoma | 08/23 | 12/23 | | |
NCT06134388: Sulfasalazine in Patients With Metastatic Colorectal Cancer |
|
|
| Recruiting | 3 | 50 | RoW | Sulfasalazine | Tanta University | Metastatic Colorectal Cancer | 09/25 | 09/26 | | |
NCT03680261: Enriched-CRT 2017: Advanced Gastric Cancer With LN+ and LVI+, Chemotherapy vs. Chemoradiotherapy |
|
|
| Not yet recruiting | 3 | 556 | RoW | chemoradiotherapy, Study group (CRT), chemotherapy, Control group (CT) | Shanghai Zhongshan Hospital | Gastric Cancer | 09/23 | 09/23 | | |
PEPCORLI, NCT02912052: Perioperative Chemotherapy VS Postoperative Chemotherapy for the Treatment of Colon Cancer With Resectable Liver Metastasis |
|
|
| Not yet recruiting | 3 | 240 | RoW | Peri-operative chemotherapy, XELOX, postoperative chemotherapy | The First Affiliated Hospital with Nanjing Medical University | Colon Cancer | 10/23 | 10/23 | | |
NCT03780049: HAIC Plus H101 vs HAIC Alone for Unresectable HCC at BCLC A-B |
|
|
| Recruiting | 3 | 304 | RoW | HAIC of FOLFOX, Hepatic artery infusion chemotherapy of oxaliplatin , fluorouracil, and leucovorin, H101, Recombinant Human Type-5 Adenovirus, Placebos, normal saline | Sun Yat-sen University | Hepatocellular Carcinoma | 10/23 | 10/23 | | |
NCT04103398: TACE Plus Sorafenib Versus TACE Alone for Recurrent Intermediate Hepatocellular Carcinoma |
|
|
| Completed | 3 | 162 | RoW | TACE+sorafenib, TACE | Sun Yat-sen University | Hepatocellular Carcinoma, Sorafenib, Transarterial Chemoembolization | 12/23 | 12/23 | | |
NCT05378867: A Study Assessing the Interchangeability Between TRS003 and Bevacizumab® For CRC |
|
|
| Not yet recruiting | 3 | 126 | NA | TRS003, China-approved Bevacizumab, mFOLFOX6 | Zhejiang Teruisi Pharmaceutical Inc. | Metastatic Colorectal Cancer (CRC) | 10/23 | 07/24 | | |